James Anderson - Procyon Director

PCYN Stock  USD 0.24  0.01  4.35%   

Director

Mr. James B. Anderson is Chief Financial Officer, Director of Procyon Corporation and Vice President Operations of Amerx Health Care Corporationration, subsidiary of Procyon Corp since 2012.
Age 53
Tenure 12 years
Phone727 447 2998
Webhttps://procyoncorp.com
Anderson, a Director since 2006, has served as Chief Financial Officer since June 2005. In addition, from September 22, 2005, until that position was filled by Regina Anderson on November 1, 2005, Mr. Anderson served as Interim Chief Executive Officer. On June 28, 2005, Mr. Anderson was appointed to serve as the President of Sirius Medical Supply, Inc. Since 1993, Mr. Anderson was involved with Amerx Health Care Corporationration as its Chief Information Officer until 2005, when he was appoint VP of Operations. In 1996, Mr. Anderson became involved with Procyon Corporationration after its merger and has since performed the duties of Vice President of Operations. Prior to Mr. Anderson’s work with the Company, he was involved with importing and exporting to Russia and Direct Mail Marketing. He received a B.S. from the University of South Florida.

James Anderson Latest Insider Activity

Tracking and analyzing the buying and selling activities of James Anderson against Procyon pink sheet is an integral part of due diligence when investing in Procyon. James Anderson insider activity provides valuable insight into whether Procyon is net buyers or sellers over its current business cycle. Note, Procyon insiders must abide by specific rules, including filing SEC forms every time they buy or sell Procyon'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Procyon Management Efficiency

The company has return on total asset (ROA) of (0.0501) % which means that it has lost $0.0501 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0934) %, meaning that it created substantial loss on money invested by shareholders. Procyon's management efficiency ratios could be used to measure how well Procyon manages its routine affairs as well as how well it operates its assets and liabilities.
Procyon currently holds 694.3 K in liabilities with Debt to Equity (D/E) ratio of 0.26, which may suggest the company is not taking enough advantage from borrowing. Procyon has a current ratio of 3.94, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Procyon until it has trouble settling it off, either with new capital or with free cash flow. So, Procyon's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Procyon sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Procyon to invest in growth at high rates of return. When we think about Procyon's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 1 records

DIRECTOR Age

Breno OliveiraHypera SA
40
Procyon Corporation, together with its subsidiaries, develops and markets proprietary medical products for use in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems in the United States. The company was incorporated in 1987 and is based in Oldsmar, Florida. Procyon Corp operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 19 people. Procyon [PCYN] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Procyon Management Team

Elected by the shareholders, the Procyon's board of directors comprises two types of representatives: Procyon inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Procyon. The board's role is to monitor Procyon's management team and ensure that shareholders' interests are well served. Procyon's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Procyon's outside directors are responsible for providing unbiased perspectives on the board's policies.
James Anderson, CFO, Director and VP of Operations - Amerx Health Care Corporate
Justice Anderson, Pres CEO
George Borak, VP of Sales - Amerx Health Care Corp

Procyon Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Procyon a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Procyon

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Procyon position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Procyon will appreciate offsetting losses from the drop in the long position's value.

Moving against Procyon Pink Sheet

  0.5PTAIF PT Astra InternationalPairCorr
The ability to find closely correlated positions to Procyon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Procyon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Procyon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Procyon to buy it.
The correlation of Procyon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Procyon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Procyon moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Procyon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Procyon Pink Sheet

Procyon financial ratios help investors to determine whether Procyon Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Procyon with respect to the benefits of owning Procyon security.